Naegleriasis (also known as primary amoebic meningoencephalitis; PAM) is an almost invariably fatal infection of the brain by the free-living unicellular eukaryote Naegleria fowleri. Symptoms are meningitis-like and include headache, fever, nausea, vomiting, a stiff neck, confusion, hallucinations and seizures. Symptoms progress rapidly over around five days, and death usually results within one to two weeks of symptoms.
|Other names||Primary amoebic meningoencephalitis (PAM), amebic encephalitis, naegleria infection, amoebic meningitis|
|Histopathology of primary amebic meningoencephalitis due to Naegleria fowleri. Direct fluorescent antibody stain.|
|Symptoms||Fever, vomiting, stiff neck, seizures, poor coordination, confusion|
|Causes||Deep nasal inhalation of Naegleria fowleri organisms from contaminated freshwater.|
|Risk factors||Roughly 75% of cases infect males; most cases are children or adolescents|
|Differential diagnosis||Bacterial or fungal meningitis|
|Prevention||Noseclips when swimming in fresh water, or avoiding fresh water environments, and proper chlorination of swimming pools|
|Treatment||Miltefosine, fluconazole, amphotericin B, voriconazole, targeted temperature management|
|Prognosis||98.5% fatality rate; some, but not all, survivors have permanent neurological damage|
N. fowleri is typically found in warm bodies of fresh water, such as ponds, lakes, rivers and hot springs. It is also found in an amoeboid or temporary flagellate stage in soil, poorly maintained municipal water supplies, water heaters, near warm-water discharges of industrial plants and in poorly chlorinated or unchlorinated swimming pools. There is no evidence of it living in salt water. As the disease is rare, it is often not considered during diagnosis.
Although infection occurs very rarely, it almost inevitably results in death. Of the 450 or so naegleriasis cases in the past 60 years, only seven have survived, implying a case fatality rate of 98.5%.
Signs and symptomsEdit
Onset of symptoms begins one to nine days following exposure (with an average of five). Initial symptoms include changes in taste and smell, headache, fever, nausea, vomiting, back pain, and a stiff neck. Secondary symptoms are also meningitis-like including confusion, hallucinations, lack of attention, ataxia, cramp and seizures. After the start of symptoms, the disease progresses rapidly over three to seven days, with death usually occurring anywhere from seven to fourteen days later, although it can take longer. In 2013, a man in Taiwan died 25 days after being infected by Naegleria fowleri.
It affects healthy children or young adults who have recently been exposed to bodies of fresh water. Some people have presented with a clinical triad of edematous brain lesions, immune suppression and fever.. Scientists speculate that lower age groups are at a higher risk of contracting the disease because adolescents have a more underdeveloped and porous cribriform plate, an organ which the amoeba travels through to reach the brain .
Cause of symptoms and diseaseEdit
N. fowleri invades the central nervous system via the nose, specifically through the olfactory mucosa of the nasal tissues. This usually occurs as the result of the introduction of water that has been contaminated with N. fowleri into the nose during activities such as swimming, bathing or nasal irrigation.
The amoeba follows the olfactory nerve fibers through the cribriform plate of the ethmoid bone into the skull. There, it migrates to the olfactory bulbs and subsequently other regions of the brain, where it feeds on the nerve tissue. The organism then begins to consume cells of the brain, piecemeal, by means of an amoebostome, a unique actin-rich sucking apparatus extended from its cell surface. It then becomes pathogenic, causing primary amoebic meningoencephalitis (PAM or PAME).
Primary amebic meningoencephalitis presents symptoms similar to those of bacterial and viral meningitis. Upon abrupt disease onset, a plethora of problems arise. Endogenous cytokines, which release in response to pathogens, affect the hypothalamus’ thermoregulatory neurons and cause a rise in body temperature . Additionally, cytokines may act on the vascular organ of the lamina terminalis, leading to the synthesis of prostaglandin (PG) E2 which acts on the hypothalamus, resulting in an increase in body temperature . Also, the release of cytokines and exogenous exotoxins coupled with an increase in intracranial pressure stimulate nociceptors in the meninges  creating pain sensations.
The release of cytotoxic molecules in the central nervous system results in extensive tissue damage and necrosis, such as damage to the olfactory nerve through lysis of nerve cells and demyelination . Specifically, the olfactory nerve and bulbs become necrotic and hemorrhagic . Spinal flexion leads to nuchal rigidity, or stiff neck, due to the stretching of the inflamed meninges . The increase in intracranial pressure stimulates the area postrema to create nausea sensations which may lead to brain herniation and damage to the reticular formation . Ultimately, the increase in cerebrospinal fluid from inflammation of the meninges increases intracranial pressure and leads to the destruction of the central nervous system. Although it is unknown of the exact pathophysiology behind the seizures caused by PAM, scientists speculate the seizures arise from altered meningeal permeability  caused by increased intracranial pressure.
Naegleria fowleri propagates in warm, stagnant bodies of freshwater (typically during the summer months), and enters the central nervous system after insufflation of infected water by attaching itself to the olfactory nerve. It then migrates through the cribriform plate and into the olfactory bulbs of the forebrain, where it multiplies itself greatly by feeding on nerve tissue.
N. fowleri can be grown in several kinds of liquid axenic media or on non-nutrient agar plates coated with bacteria. Escherichia coli can be used to overlay the non-nutrient agar plate and a drop of cerebrospinal fluid sediment is added to it. Plates are then incubated at 37 °C and checked daily for clearing of the agar in thin tracks, which indicate the trophozoites have fed on the bacteria.
Detection in water is performed by centrifuging a water sample with E. coli added, then applying the pellet to a non-nutrient agar plate. After several days, the plate is microscopically inspected and Naegleria cysts are identified by their morphology. Final confirmation of the species' identity can be performed by various molecular or biochemical methods.
Confirmation of Naegleria presence can be done by a so-called flagellation test, where the organism is exposed to a hypotonic environment (distilled water). Naegleria, in contrast to other amoebae, differentiates within two hours into the flagellate state. Pathogenicity can be further confirmed by exposure to high temperature (42 °C): Naegleria fowleri is able to grow at this temperature, but the nonpathogenic Naegleria gruberi is not.
Michael Beach, a recreational waterborne illness specialist for the Centers for Disease Control and Prevention, stated in remarks to the Associated Press that wearing of nose-clips to prevent insufflation of contaminated water would be effective protection against contracting PAM, noting that "You'd have to have water going way up in your nose to begin with".
Advice stated in the press release from Taiwan's Centers for Disease Control recommended people prevent fresh water from entering the nostrils and avoid putting their heads down into fresh water or stirring mud in the water with feet. When starting to suffer from fever, headache, nausea, or vomiting subsequent to any kind of exposure to fresh water, even in the belief that no fresh water has traveled through the nostrils, people with such conditions should be carried to hospital quickly and make sure doctors are well-informed about the history of exposure to fresh water.
On the basis of the laboratory evidence and case reports, heroic doses of amphotericin B have been the traditional mainstay of PAM treatment since the first reported survivor in the United States in 1982.
Treatment has often also used combination therapy with multiple other antimicrobials in addition to amphotericin, such as fluconazole, miconazole, rifampicin and azithromycin. They have shown limited success only when administered early in the course of an infection. Fluconazole is commonly used as it has been shown to have synergistic effects against naegleria when used with amphotericin in-vitro.
While the use of rifampicin has been common, including in all four North American cases of survival, its continued use has been questioned. It only has variable activity in-vitro and it has strong effects on the therapeutic levels of other antimicrobials used by inducing cytochrome p450 pathways.
In 2013, two successfully treated cases in the United States utilized the medication miltefosine. As of 2015, there was no data on how well miltefosine is able to reach the central nervous system. As of 2015 the U.S. CDC offered miltefosine to doctors for the treatment of free-living ameobas including naegleria. In one of the cases, a 12-year-old female, was given miltefosine and targeted temperature management to manage cerebral edema that is secondary to the infection. She survived with no neurological damage. The targeted temperature management commingled with early diagnosis and the miltefosine medication has been attributed with her survival. On the other hand, the other survivor, an 8-year-old male, was diagnosed several days after symptoms appeared and was not treated with targeted temperature management; however, he was administered the miltefosine. He suffered what is likely permanent neurological damage.
In 2016, a 16-year-old boy also survived PAM. He was treated with the same protocols of the 12-year-old female in 2013. He recovered making a near complete neurological recovery; however, he has stated that learning has been more difficult for him since contracting the disease.
This section needs to be updated.November 2019)(
Since its first description in the 1960s, only seven people worldwide have been reported to have survived PAM as of 2015, including three in the United States and one in Mexico; one of the US survivors had brain damage that is probably permanent. However, there are 2 documented surviving cases in the United States who made a full recovery with no neurological damage; they were both treated with the same protocols.  Less than 1% of people with naegleriasis survive.
The disease is rare and highly lethal: there have only been 300 cases as of 2008. Drug treatment research at Aga Khan University in Pakistan has shown that in-vitro drug susceptibility tests with some FDA approved drugs used for non-infectious diseases (digoxin and procyclidine were shown to be most effective of the drugs studied) have proved to kill Naegleria fowleri with an amoebicidal rate greater than 95%. The same source has also proposed a device for drug delivery via the transcranial route to the brain.
In the US, the most common states with cases reported of PAM from N. fowleri are the southern states, with Texas and Florida having the highest prevalence. The most commonly affected age group is 5–14 year olds (those who play in water). The number of cases of infection could increase due to climate change, and was posited as the reason for three cases in Minnesota in 2010, 2012, and 2015.
As of 2013, numbers of reported cases were expected to increase, simply because of better-informed diagnoses being made both in ongoing cases and in autopsy findings.
This form of nervous system infection by amoeba was first documented in Australia in 1965. In 1966, four cases were reported in the USA. By 1968 the causative organism, previously thought to be a species of Acanthamoeba or Hartmannella, was identified as Naegleria. This same year, occurrence of sixteen cases over a period of two years (1963–1965) was reported in Ústí nad Labem, Czechoslovakia. In 1970, the species of amoeba was named N. fowleri.
Australian physicians Fowler and Carter first described human disease caused by amebo-flagellates in Adelaide in 1965. Their work on amebo-flagellates has provided an example of how a protozoan can effectively live both freely in the environment, and in a human host. Since 1965, more than 144 cases have been confirmed in different countries. In 1966, Fowler termed the infection resulting from N. fowleri primary amoebic meningoencephalitis (PAM) to distinguish this central nervous system (CNS) invasion from other secondary invasions made by other amoebae such as Entamoeba histolytica. A retrospective study determined the first documented case of PAM possibly occurred in Britain in 1909.
The species Naegleria fowleri was named for Mathieu Naegler (1867–1934), a French parasitologist and zoologist who discovered the it for the first time in 1899, and Malcolm Fowler (1924–1974), the Australian doctor who described the distinct disease process of the pathogen in Australia in 1965.
Society and cultureEdit
Naegleria fowleri is also known as the "brain-eating amoeba". The term has also been applied to Balamuthia mandrillaris, causing some confusion between the two; Balamuthia mandrillaris is unrelated to Naegleria fowleri, however, and causes a different disease called granulomatous amoebic encephalitis. Unlike naegleriasis, which is usually seen in people with normal immune function, granulomatous amoebic encephalitis is usually seen in people with poor immune function, such as those with HIV/AIDS or leukemia.
Improving case detection through increased awareness, reporting, and information about cases might enable earlier detection of infections, provide insight into the human or environmental determinants of infection, and allow improved assessment of treatment effectiveness.
- Fortin, Jacey (25 July 2019). "Man Dies of 'Brain-Eating' Amoeba After Swimming in Lake". The New York Times. Retrieved 1 April 2020.
- Centers for Disease Control and Prevention (CDC) (2008). "Primary amebic meningoencephalitis – Arizona, Florida, and Texas, 2007". MMWR. Morbidity and Mortality Weekly Report. 57 (21): 573–7. PMID 18509301.
- "Naegleria fowleri — Primary Amebic Meningoencephalitis (PAM) — Amebic Encephalitis". 23 April 2015. Retrieved 17 January 2016.
- Grace, Eddie; Asbill, Scott; Virga, Kris (1 November 2015). "Naegleria fowleri: Pathogenesis, Diagnosis, and Treatment Options". Antimicrobial Agents and Chemotherapy. 59 (11): 6677–6681. doi:10.1128/AAC.01293-15. ISSN 0066-4804. PMC 4604384. PMID 26259797.
- "Illness & Symptoms | Naegleria fowleri | CDC". www.cdc.gov. 4 April 2019.
- "The Centers for Disease Control and Prevention, Division of Parasitic Diseases – Naegleria fowleri—Primary Amoebic Meningoencephalitis (PAM)—General Information". Retrieved 26 May 2014.
- "6 die from brain-eating amoeba after swimming". NBC News. Associated Press. 28 September 2007.
- one death in September 2018 was the first confirmed case of the infection in the United States since 2016 (nytimes.com: A Man Died After Being Infected With a Brain-Eating Amoeba. Here Are the Facts)
- Elizabeth Cohen, Senior Medical Correspondent. "Brain-eating amoeba survivor to begin school". CNN. Retrieved 10 September 2019.
- Talaro, Kathleen (2015). Foundations in microbiology. New York, NY: McGraw-Hill Education. p. 695. ISBN 978-0-07-352260-9.
- "CDC—01 This Page Has Moved: CDC Parasites Naegleria". Retrieved 27 July 2015.
- Su MY, Lee MS, et al. (April 2013). "A fatal case of Naegleria fowleri meningoencephalitis in Taiwan". Korean J Parasitol. 51 (2): 203–6. doi:10.3347/kjp.2013.51.2.203. PMC 3662064. PMID 23710088.
- Mayer, Peter (2011). "Amebic encephalitis". Surgical Neurology International. 50 (2): 50. doi:10.4103/2152-7806.80115. PMC 3114370. PMID 21697972.
- Marciano-Cabral, F; John, DT (1983). "Cytopathogenicity of Naegleria fowleri for rat neuroblastoma cell cultures: scanning electron microscopy study". Infection and Immunity. 40 (3): 1214–7. PMC 348179. PMID 6852919.
- Montgomery, Katherine. "Meningitis". McMaster Pathophysiology Review. Retrieved 29 March 2020.
- Walter, Edward James; Hanna-Jumma, Sameer; Carraretto, Mike; Forni, Lui (14 July 2016). "The pathophysiological basis and consequences of fever". Critical Care. 20 (1): 200. doi:10.1186/s13054-016-1375-5. ISSN 1364-8535.
- Pugh, J. Jeffrey; Levy, Rebecca A. (21 September 2016). "Naegleria fowleri: Diagnosis, Pathophysiology of Brain Inflammation, and Antimicrobial Treatments". ACS Chemical Neuroscience. 7 (9): 1178–1179. doi:10.1021/acschemneuro.6b00232. Retrieved 29 March 2020.
- Fero, Kelly. "Naegleria fowleri". web.stanford.edu. Retrieved 29 March 2020.
- Cervantes-Sandoval I, Serrano-Luna Jde J, García-Latorre E, Tsutsumi V, Shibayama M (September 2008). "Characterization of brain inflammation during primary amoebic meningoencephalitis". Parasitol. Int. 57 (3): 307–13. doi:10.1016/j.parint.2008.01.006. PMID 18374627.
- Donald C. Lehman; Mahon, Connie; Manuselis, George (2006). Textbook of Diagnostic Microbiology (3rd ed.). Philadelphia: Saunders. ISBN 978-1-4160-2581-8.[page needed]
- Pougnard, C.; Catala, P.; Drocourt, J.-L.; Legastelois, S.; Pernin, P.; Pringuez, E.; Lebaron, P. (2002). "Rapid Detection and Enumeration of Naegleria fowleri in Surface Waters by Solid-Phase Cytometry". Applied and Environmental Microbiology. 68 (6): 3102–7. doi:10.1128/AEM.68.6.3102-3107.2002. PMC 123984. PMID 12039772.
- "6 die from brain-eating amoeba in lakes", Chris Kahn/Associated Press, 9/28/07
- "福氏內格里阿米巴腦膜腦炎感染病例罕見，但致死率高，籲請泡溫泉及從事水上活動之民眾小心防範". 衛生福利部疾病管制署 (in Chinese). 26 October 2013. Retrieved 14 October 2017. This article incorporates text from this source, which is in the public domain.
- The American Heritage Stedman's Medical Dictionary. Houghton Mifflin Company. 2004.
- Bauman, Robert W. (2009). "Microbial Diseases of the Nervous System and Eyes". Microbiology, With Diseases by Body System (2nd ed.). San Francisco: Pearson Education. p. 617.
- Diaz, Johnny. "Teen who survived brain-eating amoeba says sickness gave him more positive outlook". sun-sentinel.com. Retrieved 15 April 2020.
- Güell, Oriol (12 October 2018). "Una niña de Toledo sobrevive al primer caso en España de la ameba comecerebros". El País. Retrieved 11 November 2018.
- Caruzo G, Cardozo J (October 2008). "Primary amoebic meningoencephalitis: a new case from Venezuela". Trop Doct. 38 (4): 256–7. doi:10.1258/td.2008.070426. PMID 18820207.[permanent dead link]
- Mannan Baig Abdul; Kulsoom Huma; Ahmed Khan Naveed (2014). "Primary amoebic meningoencephalitis: amoebicidal effects of clinically approved drugs against Naegleria fowleri". Journal of Medical Microbiology. 63 (Pt 5): 760–762. doi:10.1099/jmm.0.072306-0. PMID 24493160.
- Baig Abdul M., Khan Naveed A. (2014). "Novel Chemotherapeutic Strategies in the Management of Primary Amoebic Meningoencephalitis Due to Naegleria fowleri". CNS Neuroscience & Therapeutics. 20 (3): 289–290. doi:10.1111/cns.12225. PMC 6493040. PMID 24456292.
- “Number of Case-Reports of Primary Amebic Meningoencephalitis Caused by Naegleria Fowleri (N=133) by State of Exposure*— United States, 1962–2014.” CDC.gov, CDC, www.cdc.gov/parasites/naegleria/pdf/naegleria-state-map-2014.pdf.
- Kemble SK, Lynfield R, et al. (March 2012). "Fatal Naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism". Clin Infect Dis. 54 (6): 805–9. doi:10.1093/cid/cir961. PMID 22238170.
- Lorna Benson (9 July 2015). "Has deadly water amoeba found a home in Minnesota?". Retrieved 5 September 2016.
- Kanwal Farooqi M, Ali S, Ahmed SS (May 2013). "The paradox of primary amoebic meningoencephalitis—a rare disease, but commonly misdiagnosed". J Pak Med Assoc. 63 (5): 667. PMID 23758009.
- Fowler, M.; Carter, R. F. (September 1965). "Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report". British Medical Journal. 2 (5464): 740–2. doi:10.1136/bmj.2.5464.734-a. PMC 1846173. PMID 5825411.
- Symmers, W. S. C. (November 1969). "Primary amoebic meningoencephalitis in Britain". British Medical Journal. 4 (5681): 449–54. doi:10.1136/bmj.4.5681.449. PMC 1630535. PMID 5354833.
- Červa, L.; Novák, K. (April 1968). "Ameobic meningoencephalitis: sixteen fatalities". Science. 160 (3823): 92. Bibcode:1968Sci...160...92C. doi:10.1126/science.160.3823.92. PMID 5642317.
- Gutierrez, Yezid (15 January 2000). "Chapter 6: Free Living Amebae". Diagnostic Pathology of Parasitic Infections with Clinical Correlations (2 ed.). USA: Oxford University Press. pp. 114–115. ISBN 978-0-19-512143-8.
- Butt, Cecil G. (1966). "Primary Amebic Meningoencephalitis". New England Journal of Medicine. 274 (26): 1473–6. doi:10.1056/NEJM196606302742605. PMID 5939846.
- Fowler, M; Carter, RF (1965). "Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report". British Medical Journal. 2 (5464): 740–2. doi:10.1136/bmj.2.5464.734-a. PMC 1846173. PMID 5825411.
- Symmers, WC (1969). "Primary amoebic meningoencephalitis in Britain". British Medical Journal. 4 (5681): 449–54. doi:10.1136/bmj.4.5681.449. PMC 1630535. PMID 5354833.
- Shadrach, WS; Rydzewski, K; Laube, U; Holland, G; Ozel, M; Kiderlen, AF; Flieger, A (May 2005). "Balamuthia mandrillaris, free-living ameba and opportunistic agent of encephalitis, is a potential host for Legionella pneumophila bacteria". Applied and Environmental Microbiology. 71 (5): 2244–9. doi:10.1128/AEM.71.5.2244-2249.2005. PMC 1087515. PMID 15870307.
- "IMDB, Euphoria: Part 1". Retrieved 14 June 2014.
- "IMDB, Euphoria: Part 2". Retrieved 14 June 2014.
- Wessel, Lindzi (22 July 2016). "Scientists hunt for drug to kill deadly brain-eating amoeba". STAT News.
- Kim, J.-H.; Jung, S.-Y.; Lee, Y.-J.; Song, K.-J.; Kwon, D.; Kim, K.; Park, S.; Im, K.-I.; Shin, H.-J. (2008). "Effect of Therapeutic Chemical Agents In Vitro and on Experimental Meningoencephalitis Due to Naegleria fowleri". Antimicrobial Agents and Chemotherapy. 52 (11): 4010–6. doi:10.1128/AAC.00197-08. PMC 2573150. PMID 18765686.